Objective: The aim of this study was to assess the efficacy and toxicity of the combination of paclitaxel and nedaplatin as a first-line chemotherapy for patients with advanced esophageal cancer. Methods: Patients with advanced esophageal cancer received 175 mg/m 2 of paclitaxel over a 3 h infusion, followed by nedaplatin 80 mg/m 2 in a 1 h infusion on day 1 every 3 weeks until the documented disease progression, unacceptable toxicity or patient's refusal. Results: Between March 2005 and December 2007, 48 patients entered in the study. Fortysix (95.8%) of the 48 patients were assessable for response. The overall response rate was 41.7% (95% CI, 27.8 -55.7%) with 2 complete responses and 18 partial responses. The median follow-up period was 20.5 months (range, 12.5 -27.2 months). The median overall time to progression and overall survival (OS) were 6.1 months (95% CI, 4.8-7.4 months) and 11.5 months (95% CI, 9.1 -13.9 months), respectively. The estimate of OS at 12 and 24 months was 43.8% (95% CI, 29.7 -77.8%) and 10.4% (95% CI, 1.8 -19.1%), respectively. Most patients experienced anemia, during their course of therapy with 6 (13.0%) patients for grade 3/4 anemia, and grade 1 or 2 anemia was detected in 23 (50%) patients. Grade 3 leucopenia, neutropenia and thrombocytopenia were documented in 8 (17.4%), 9 (17.4%) and 2 (4.3%) patients, respectively. Grade 3 nausea and vomiting were detected in 3 (6.5%) and 2 (4.3%) patients, respectively. Two patients (4.3%) were hospitalized because of treatment-related complications. The treatment was well tolerated and no toxic death occurred. Conclusions: Combination of paclitaxel and nedaplatin is a tolerated treatment modality with promising activity in previously untreated advanced esophageal cancer.
INTRODUCTION
Patients with esophageal cancer generally have a poor prognosis, because the majority of them already have locally unresectable or metastatic disease at presentation. Furthermore, even after surgery with curative intent, local recurrences and/or distant metastases are detected in approximately two-thirds of the patients within 5 years of follow-up (1) . Metastatic or recurrent esophageal cancer is an incurable disease, and treatment outcomes for these patients are unsatisfactory because of the lack of effective therapies. Palliative chemotherapy may result in local and distant tumor and symptom control. The effect of chemotherapy on survival is unclear, mainly owing to a lack of randomized trials. The most frequently used chemotherapy regimen for patients with metastatic disease is a combination of 5-fluorouracil (5-FU) and cisplatin, with response rates (RRs) ranging from 15% to 45% (2) . However, treatment with 5-FU and cisplatin can induce severe toxicity (3) . Besides, most patients have to be hospitalized for this treatment. Accordingly, it is important to develop effective and well-tolerated chemotherapeutic agents for treatment.
Paclitaxel, a new broad-spectrum cytotoxic antineoplastic, has shown some promising responses against digestive tract cancer. As a single agent, paclitaxel has been shown to achieve an RR of 32% in esophageal cancer and gastroesophageal junction cancer (4 (5 -9) . However, toxicity for combination therapy was significant and included severe myelosuppression, gastrointestinal (GI) and neurologic toxicity, and a significant rate of hospitalization for treatment-related complications. So, trials have been design to develop new combination treatments that could achieve similar outcome and induce relatively minimal toxicities. Nedaplatin (cis-diammine-glycolate platinum, NDP) is a second-generation platinum derivative developed in Japan, and several in vitro studies have demonstrated that nedaplatin has equivalent antitumor activity to cisplatin, with less nephrotoxicity (10, 11) . Consistent with the results of the in vitro studies, recent Phase I trails of nedaplatin in combination with other agents have shown modest antitumor activity for several human tumors, with less nephrotoxicity and GI toxicity (12 -14) . On the basis of these promising results, we conducted a Phase II study in order to assess the efficacy and toxicity of the combination of paclitaxel and nedaplatin as a first-line chemotherapy for patients with advanced esophageal cancer.
PATIENTS AND METHODS

ELIGIBILITY CRITERIA
Eligible patients had histologically proven metastatic or local regional unresectable carcinoma of the esophagus and at least one unidimensionally measurable lesion !20 mm using conventional computed tomography (CT) or magnetic resonance imaging scan or !10 mm using spiral CT scan had to be present. No prior chemotherapy for locally advanced or metastatic disease was allowed. Patients were required to be aged at least 18 years to have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 and a life expectancy of !3 months. Other criteria included adequate hematological, renal and hepatic functions as defined by: granulocyte count of at least 1500 mm 23 and platelet count 100 000 mm 23 ; serum creatinine 1.25 Â the upper normal limit (ULN); aspartate aminotransferase and alanine aminotransferase 3 Â ULN ( 5 Â ULN in the case of liver metastases) and bilirubin 1.25 Â ULN. Patients who received 5-FU containing adjuvant chemotherapy for nonmetastatic disease .6 months from the date of study entry were eligible for the study. No history of malignancy, apart from non-melanomatous skin cancer, curatively treated carcinoma in situ of the cervix, or a 'cured' malignancy more than 5 years before enrollment was allowed. Patients with evidence of central nervous system metastases, a lack of physical integrity of the upper GI tract, a malabsorption syndrome or an inability to take oral medication were excluded. Gastroesophageal junction tumors were excluded from the study. Patients were not eligible if they had a pre-existing motor or sensory neurotoxicity .grade 1 according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC version 3.0). The Ethics Committee at Shanghai Ruijin Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, approved the study and written informed consent was obtained.
STUDY TREATMENT
Patients received 175 mg/m 2 of paclitaxel over a 3 h infusion, followed by nedaplatin 80 mg/m 2 in a 1 h infusion on day 1 every 3 weeks until the documented disease progression, unacceptable toxicity or patient's refusal. These doses were based on a Phase I trial of chemotherapy using paclitaxel and nedaplatin in chemotherapy-naïve patients with unresectable squamous cell carcinoma (SCC) (14) . Paclitaxel infusions preceded the administration of nedaplatin in the current study, as the interaction of nedaplatin and paclitaxel is highly schedule-dependent (15) . As prophylactic agents, dexamethasone (iv, 20 mg), promethazine (iv, 25 mg) and cimetidine (iv, 400 mg) were given 30 min before paclitaxel administration. All patients received adequate antiemetic therapy prior to chemotherapy. Granulocyte colony-stimulating factor was administered at physician's discretion or taking insurance status of the countries in considerations.
DOSE MODIFICATION
The next course of treatment was only begun when the neutrophil count was !1.5 Â 10 9 /l, platelet count !100 Â 10 9 /l and any other treatment-related toxicities were less than or equal to grade 1; otherwise, treatment was withheld for up to 2 weeks. If adverse events did not improve to grade 0 or 1 after 2 weeks, the patients were excluded from the study. Treatment was continued at the same dose if patients experienced grade 1 toxicities or other toxicities considered by the investigator unlikely to become serious or life threatening (e.g. alopecia). For all other treatment-related adverse events with a grade 2 intensity or higher, the dose modification scheme described below was implemented. The subsequent cycle of treatment was reduced by 20% doses of paclitaxel and nedaplatin in the case of a repeated grade 2 or any grade 3 toxicity, and reduced by 40% in the case of a repeated grade 3 or any grade 4 toxicity during the preceding cycle. If a dose reduction of .40% was required, the patients were excluded from the study.
RESPONSE TO TREATMENT AND ADVERSE EFFECTS
Pre-treatment evaluation included a detailed history taking, a physical examination and routine blood examinations. Chest X-ray, ECG, upper GI endoscopies, chest and upper abdominal CT scans and other appropriate procedures were also performed. After every two cycles of treatment, response was evaluated by two independent experts using RECIST criteria. Of the lesions observed prior to treatment, a maximum of five measurable lesions from each metastasized organ up to a total of 10 lesions were selected as target lesions. In the cases of partial response (PR) or complete response (CR), a confirmative CT scan was performed 6 weeks later and this was followed by a CT scan after every two treatment cycles. After discontinuation of treatment, follow-up visits were done every 3 months to document late toxic effects, disease progression and survival. Toxicity was reported using an NCI-CTC version 3.0 toxicity scale.
STATISTICAL ANALYSIS
The current trial used a two-stage optimal design, as proposed by Simon (16) , with an 80% power to accept the hypothesis and 5% significance to reject the hypothesis. Plus, the current trial was designed to detect an RR of 40% when compared with a minimal, clinically meaningful RR of 20%. Allowing for a follow-up loss rate of 10%, the total sample size was 48 patients with a measurable disease. At the first stage, if there were fewer than five responses out of the initial 19 patients, an early termination of the study was required. All enrolled patients were included in the intention-to-treat analysis of efficacy. The duration of response, time to progression (TTP) and survival analyses were all estimated using the Kaplan -Meier method. The duration of response was defined as the interval from the onset of a CR or PR until evidence of disease progression was found. Meanwhile, the TTP was calculated from the initiation of chemotherapy to the date of disease progression, whereas overall survival (OS) was measured from the initiation of chemotherapy to the date of the last follow-up or death. The statistical data were obtained using an SPSS software package (SPSS 11.5 Inc., Chicago, IL, USA). Table 1 . The median age was 56 (range, 29 -73) years, with 38 males and 10 females. The majority of the patients (85.4%) had either ECOG performance status 0 or 1. Most of patients (95.8%) had pathology of SCC, and others were adenocarcinoma (4.2%), and no patient had gastroesophageal junction carcinomas. Twenty-seven (56.3%) patients had undergone esophagectomy, and .85% of the patients received prior post-operative 5-FU-based adjuvant chemotherapy with or without radiotherapy .6 months from the date of study entry. The median time to recurrence from the adjuvant chemotherapy with or without radiotherapy was 15.5 months (range, 8.5 -23.5 months). At the time of treatment with the most common site of metastasis being lymph node (68.8%) followed by liver (20.8%), lung (10.4%) and bone (10.4%).
RESULTS
PATIENT CHARACTERISTICS
EFFICACY AND SURVIVAL
Forty-six (95.8%) of the 48 patients were assessable for response, of the two patients not assessable, both were lost to follow-up after the first cycle of the treatment. All efficacy data are reported using the intention-to-treat principle. The overall RR was 41.7% (95% CI, 27.8 -55.7%) with 2 CRs and 18 PRs. Of these 20 responses, 6 (30.0%) were observed after two cycles, 12 (60.0%) after four cycles and 2 (10.0%) after six cycles ( Table 2 ). The median follow-up period was 20.5 months (range, 12.5 -27.2 months). The median overall TTP was 6.1 months (95% CI, 4.8 -7.4 months). The estimated median OS was 11.5 months (95% 
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TOXICITY
Forty-six (95.8%) patients were assessable for safety. A total of 206 cycles of paclitaxel and nedaplatin were administered to the 46 patients, with the median number of cycles administered per patient of 4 (range, 2 -10 cycles). Dose reduction was required in nine cycles (out of 206), but no delay in the start of chemotherapy was required. The treatment was well tolerated and no toxic death occurred. Toxic effects observed during the study are listed in Table 3 . The most common toxic effects were anemia, leucopenia, neutropenia, nausea, vomiting, anorexia and fatigue. Most patients experienced anemia, during their course of therapy with 13.0% of the patients (n ¼ 6) for grade 3/4 anemia, and grade 1 or 2 anemia was detected in 50% of the patients (n ¼ 23). Grade 3 leucopenia, neutropenia and thrombocytopenia were documented in 8 (17.4%), 9 (17.4%) and 2 (4.3) patients, respectively. Nausea, vomiting, anorexia, fatigue and neuropathy were the most common non-hematological toxicities. Grade 3 nausea and vomiting were detected in 3 (6.5%) and 2 (4.3%) patients, respectively. Grade 1/2 nausea, vomiting, anorexia, fatigue and neuropathy were observed in 15 (32.6%), 22 (47.8%), 22 (47.8%), 19 (41.3%) and 23 (50.0%) patients, respectively. However, no grade 4 non-hematologic toxicity was observed in this study. Two patients (4.3%) were hospitalized because of treatment-related complications (one because of infections and another because of general weakness).
DISCUSSION
Although there is no standard chemotherapy regimen for advanced esophageal cancer, various kinds of chemotherapy regimens have been investigated in an attempt to prolong survival and improve quality of life. The most commonly used regimen as the first-line chemotherapy is the combination of cisplatin (100 mg/m 2 on day 1) and 5-FU (1000 mg/m 2 /day continuous infusion for 96 -120 h) in metastatic esophageal cancer (17) . The randomized Phase II study comparing cisplatin/5-FU to cisplatin alone in advanced squamous cell esophageal cancer showed that the combination arm was superior in terms of RR of 35% when compared with cisplatin alone arm (RR ¼ 19%), and OS (33 Figure 1 . Time to disease progression and overall survival for intention-to-treat population (n ¼ 48). Jpn J Clin Oncol 2009;39 (9) 585 vs. 28 weeks, respectively) (18) . However, the toxicity was prominent with high treatment-related deaths (16%). In addition, continuous infusion of 5-FU requires an indwelling venous access, which provides a source for venous thrombosis and sepsis and makes therapy burdensome to the patient. More recently, newer agents such as taxanes (paclitaxel and docetaxel), vinorelbine, irinotecan, capecitabine, oxaliplatin and nedaplatin have been investigated as single agents or in combination in pre-operative or advanced settings (19) . This Phase II study showed that the combination of paclitaxel 175 mg/m 2 and nedaplatin 80 mg/m 2 was active as the first-line treatment in patients with advanced esophageal cancer. Given the fact that a great majority of patients had metastatic disease at the time of treatment, the RR was relatively high with 41.7% (95% CI, 27.8 -55.7%). After a median follow-up duration of 20.5 months (range, 12.5 -27.2 months), the median TTP and OS were 6.1 months (95% CI, 4.8 -7.4 months) and 11.5 months (95% CI, 9.1 -13.9 months), respectively. This study suggests that the regimen is safe with encouraging antitumor activity. Recently, several Phase II studies were published of paclitaxel and platinumbased regimens for advanced or metastatic esophageal cancer (5, 6, 8, 9, 20) . Gong et al. (20) reported that the overall RR was 43.6% and the median progression-free survival (PFS) and OS was 6 and 10 months, respectively, in a Phase II study of 39 patients with metastatic esophageal cancer treated with nedaplatin 80 mg/m 2 and paclitaxel 175 mg/m 2 . Polee et al. (8) reported that paclitaxel and cisplatin introduced a relative longer median PFS of 8 months, but the median time of OS was only 9 months. The highest median OS (13 months) was reported by Zhang et al. (9) , and the median TTP was 7 months. The results of our study can be comparable with those of these published studies.
Grade 3/4 anemia, leucopenia, neutropenia, nausea and vomiting in only 6 (13.0%), 8 (17.4%), 9 (19.6%), 3 (6.5%) and 2 (4.3%) patients, respectively. Dose reduction was required in only 9 cycles (out of 206), but no delay in the start of chemotherapy was required. These toxicities were well tolerated. No patients were discontinued from the study due to toxic effects. Nedaplatin is a second-generation platinum complex with lower renal and GI toxicities than cisplatin. Kidney accumulation of nedaplatin was lower than that of cisplatin, and nedaplatin showed lower nephrotoxicities than cisplatin. In contrast to cisplatin, nedaplatin does not require a large amount of fluid infusion (11) . There were no treatment-related deaths during this study. Only two patients (4.3%) were hospitalized because of treatment-related complications. In contrast, hospitalization rates of other outpatient regimens for esophageal cancer were reported to be much higher (8, 21) .
In conclusion, combination of paclitaxel and nedaplatin is a tolerated treatment modality with promising activity in previously untreated advanced esophageal cancer. However, the development of more effective therapy, particularly with the addition of new biological agents such as bevacizumab, cetuximab or others, to the combination of paclitaxel and nedaplatin is warranted to improve the prognosis of advanced esophageal cancer.
